Vapotherm's Asthma Therapy More Effective Than Standard Oxygen Therapy In Kids

Vapotherm Inc (NASDAQ: VAPO) announced the presentation of an investigator-initiated clinical trial at the European Respiratory Society International Congress 2023, a "high flow humidified oxygen as an early intervention in children with acute severe asthma — a feasibility randomized controlled trial."

The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England.

Children who arrived at the hospital emergency department with acute, severe asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to HVNI or standard nasal oxygen therapy. 

While 86% (19/22) of children treated with standard oxygen required escalation of therapy, only 61% (17/28) of children treated with HVNI needed further escalation. 

In addition, children treated with HVNI met hospital discharge criteria in a median time of 29 hours, compared to 37 hours for those treated with standard oxygen.

According to the CDC and NHS, almost 5 million children in the U.S. and 1 million children in the U.K. have asthma. 

Price Action: VAPO shares are down 3.85% at $2.25 on the last check Monday.

Read Next: Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth

Photo: Shutterstock